12:00 AM
 | 
Sep 01, 2014
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Xalkori crizotinib: Phase III started

The National Clinical Trials Network (NCTN) launched the ALCHEMIST protocol to identify early stage NSCLC patients with tumors that harbor genetic mutations to understand how early intervention can improve survival outcomes for patients who have undergone complete surgical resection of tumors. The ALCHEMIST protocol comprises 3 component trials -- a screening trial (A151216) and the double-blind, placebo-controlled, U.S. Phase III AO81105 and E4512 trials.

In A151216, Response Genetics Inc. (NASDAQ:RGDX, Los Angeles, Calif.) will...

Read the full 362 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >